Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.68 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.62 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.62 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.62 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5580001 | 0.88 | ESR2 (0.68) | ESR1ESR2GRIA1CACNG8CACNG2 | |
| SCHEMBL8021778 | 0.88 | ESR2 (0.88) | ESR1ESR2GRIA1CACNG8CACNG2 | |
| SCHEMBL2327451 | 0.87 | ESR1 (0.68) | ESR1ESR2GRIA1CACNG8CACNG2 | |
| SCHEMBL10047632 | 0.86 | ESR2 (0.85) | ESR1ESR2GRIA1CACNG8CACNG2 | |
| SCHEMBL2328330 | 0.83 | ESR2 (0.70) | ESR1ESR2GRIA1CACNG8CACNG2 | |
| SCHEMBL6440249 | 0.83 | ESR2 (0.91) | ESR1ESR2GRIA1CACNG8CACNG2 | |
| SCHEMBL9007262 | 0.83 | ESR2 (0.91) | ESR1ESR2GRIA1CACNG8CACNG2 | |
| SCHEMBL6701015 | 0.81 | SIRT2 (0.68) | ESR1ESR2GRIA1CACNG8CACNG2 | |
| SCHEMBL6440186 | 0.81 | ESR2 (1.00) | ESR1ESR2GRIA1CACNG8CACNG2 | |
| SCHEMBL13486686 | 0.81 | SIRT2 (0.62) | ESR1ESR2GRIA1CACNG8CACNG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | US | disclosed |
| EP-1341768-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | AstraZeneca AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046168-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ESR2, ESRRA, ESRRB | ESR1 6/4885ESR2 1/4885GRIA1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.